Skip to Main Content

Author Details

Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
2006
67
29
PMIDPaper TitleJournal TitlePublished Year
37738504Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.Annu Rev Pharmacol Toxicol2024
36889927Defining clonal hematopoiesis of indeterminate potential: evolutionary dynamics and detection under aging and inflammation.Cold Spring Harb Mol Case Stud2023
37756546Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice.Blood Adv2023
37698624Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood Cancer Discov2023
37781631Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.bioRxiv2023
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
35896960Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.Clin Proteomics2022
35078224Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.Blood Adv2022
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
32221387Differential regulation of microRNA-15a by radiation affects angiogenesis and tumor growth via modulation of acid sphingomyelinase.Sci Rep2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
30690106Silica cloaking of adenovirus enhances gene delivery while reducing immunogenicity.J Control Release2019
31754026Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.Proc Natl Acad Sci U S A2019
31781167Identification of Novel Microsatellite Markers Flanking the <i>SMN1</i> and <i>SMN2</i> Duplicated Region and Inclusion Into a Single-Tube Tridecaplex Panel for Haplotype-Based Preimplantation Genetic Testing of Spinal Muscular Atrophy.Front Genet2019
31712634Robust Preimplantation Genetic Testing of Huntington Disease by Combined Triplet-Primed PCR Analysis of the HTT CAG Repeat and Multi-Microsatellite Haplotyping.Sci Rep2019
31648317ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.Blood Adv2019
31316003Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".Sci Transl Med2019
30924767Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells.Elife2019
31120863PI3 kinase alpha and delta promote hematopoietic stem cell activation.JCI Insight2019
30720426FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.Elife2019
30425048CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.Blood2019
29743719Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.Leukemia2018
30171048Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.Clin Cancer Res2018
29872489Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.Oncotarget2018
30279971Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.Oncotarget2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
28906323Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens.J Pediatr Hematol Oncol2017
28355571Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.Cell Rep2017
28208123Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.Oncotarget2017
29190822The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model.PLoS One2017
26095727Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance.Br J Haematol2016
26573090Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.Am J Hematol2016
26458983JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.Exp Hematol2016
26432900Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages.J Leukoc Biol2016
27705940Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Oncotarget2016
27671675FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Cancer Res2016
27581286RNAi Screening of Leukemia Cells Using Electroporation.Methods Mol Biol2016
27118405Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.Leukemia2016
27320899Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.Sci Rep2016
25109334Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.Oncogene2015
25716043First ever case of spontaneous triplet cornual pregnancy: management of laparoscopic cornual resection with modified endoloop method.BMJ Case Rep2015
24408322Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.Blood2014
25628989Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.Leuk Res Rep2014
25293778BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Blood2014
25254959Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle.PLoS One2014
24436473Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Clin Cancer Res2014
23576564Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.Cancer Res2013
24081659The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.Blood2013
24218589Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.Proc Natl Acad Sci U S A2013
  • 1 - 50 of 67

Recommended Authors

Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 1
Brett M Stevens
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 7
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 1
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 2
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 3
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 0
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 4
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 11
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 2
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 17
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 5
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 9
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 13
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 5
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 7
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 13
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 4
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 26
Ravi Bhatia
University of Alabama at Birmingham
Career Start Year 1992
Number of shared co-authors 11
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 7
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 11
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 36
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 5
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 45
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 12
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 1
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 27

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 39
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 27
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 17
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 16
Elie Traer
Oregon Health & Science University
Co-authored papers 13
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 13
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 12
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 11
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 8
Nicola Long
Oregon Health and Science University
Co-authored papers 7
Angela G Fleischman
University of California Irvine
Co-authored papers 7
Jacqueline Martinez
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Bill H Chang
Oregon Health and Science University
Co-authored papers 7
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Ryan J Mackenzie
Oregon Health & Science University, USA [2] Knight Cancer Institute
Co-authored papers 6
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 6
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Isabel English
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
David K Edwards
Exact Sciences Corporation
Co-authored papers 6
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 5
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 5
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 5
Monika A Davare
Oregon Health Sciences University
Co-authored papers 4
Jennifer Dunlap
Oregon Health & Science University
Co-authored papers 4
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Grover C Bagby
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 4
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 4
David Tyler Sweeney
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Release 1.2